Ipca Laboratories Ltd Financials
Company Logo

Ipca Laboratories Ltd Financial Statement

Ipca Laboratories Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue1659.93
Operating Expense1561.39
Net Profit-65.05
Net Profit Margin-3.92
Earning Per Share-2.56
EBIDTA92.24
Effective Tax Rate77.02

Ipca Laboratories Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual6,166.46
Operating Expenses Annual4,955.08
Operating Profit Annual1,189.31
Interest Annual120.67
Depreciation238.08
Net Profit Annual530.41
Tax Annual291.75

Ipca Laboratories Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning1,504.83
Cash Flow from Operations830.51
Cash Flow from Investing-1,355.18
Cash Flow from Financing-464.88
Cash Flow at the End515.28

Ipca Laboratories Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)21.08
PBIT Margin (%)17.08
PBT Margin (%)16.94
Net PROFIT Margin (%)8.60
Return On Networth / Equity (%)9.81
Return On Networth /Employed (%)14.12
Return On Assets (%)7.14
Total Debt / Equity (X)0.21
Asset Turnover Ratio (%)0.83

Ipca Laboratories Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2,533.17
Total Current Assets Annual3,509.89
Non Current Assets Annual5,149.38
Total Shareholders Funds Annual6,348.71
Total Assets Annual8,659.27

Ipca Laboratories Ltd Earning Calls

EPS (INR)

Expected

2.67

Reported

2.67

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Ipca Laboratories Ltd Financials

As of Jun 26, 2025, Ipca Laboratories Ltd has a market capitalization of 38,088.61 Cr. Value Research classifies it as a Large-Cap company.

Yes, Ipca Laboratories Ltd is with a debt-to-equity ratio of 0.13.

In FY 2024 , Ipca Laboratories Ltd recorded a total revenue of approximately 6,677.92 Cr marking a significant milestone in the company's financial performance.

Ipca Laboratories Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.1% annually, respectively..

Ipca Laboratories Ltd's current PE ratio is 58.53.

Ipca Laboratories Ltd's ROCE averaged 14.1% from the FY ending March 2023 to 2025, with a median of 14.3%. It peaked at 17.2% in March 2025, reflecting strong capital efficiency over the period..

Ipca Laboratories Ltd's latest EBIT is Rs. 1,062.81 Cr, surpassing the average EBIT of Rs. 933.35 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions